Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

49.2K
Overview
49.2K
Cancer Vaccines01:30

Cancer Vaccines

619
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
619
Cross-reactivity00:42

Cross-reactivity

32.1K
Overview
32.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CLEC5A/TLR2 bispecific antibody suppresses dengue virus-induced pro-inflammatory cytokines production from macrophages.

Journal of biomedical science·2026
Same author

RNP interfaces as regulatory "active sites": a repurposing strategy for small molecules targeting viral 5'-untranslated regions.

Frontiers in molecular biosciences·2026
Same author

HLA-C-derived peptide MH-1 as an early-stage intervention against SARS-CoV-2 infection.

Molecular medicine (Cambridge, Mass.)·2026
Same author

COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and <i>in vitro</i> antibody-dependent enhancement.

Frontiers in immunology·2026
Same author

Moringin as a Lead Compound for Anti-Enteroviruses and Coronaviruses Broad-Spectrum Inhibition of Viral Proteases: Comparative Evaluation With Glucomoringin and Antiviral Agents.

Journal of medical virology·2025
Same author

Intensive reassortment and frequent intercontinental transmission revealed by long-term genetic analysis of H10 avian influenza viruses in Taiwan.

Emerging microbes & infections·2025
Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026
Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026
Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026
Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026
Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.3K

Enterovirus A71 Vaccines.

Mei-Ling Li1, Shin-Ru Shih2,3,4,5, Blanton S Tolbert6

  • 1Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.

Vaccines
|March 6, 2021
PubMed
Summary
This summary is machine-generated.

Enterovirus A71 (EV-A71) causes severe hand, foot, and mouth disease. This review covers recent advancements in EV-A71 vaccines, including licensed inactivated vaccines and developing virus-like particle and recombinant VP1 vaccines.

Keywords:
Enterovirus A71Sinovacfoot and mouth disease (HFMD)handvaccine

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.4K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.6K

Related Experiment Videos

Last Updated: Nov 15, 2025

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.3K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.4K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.6K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Enterovirus A71 (EV-A71) is a primary cause of hand, foot, and mouth disease (HFMD) and herpangina.
  • EV-A71 infections can result in severe neurological complications and mortality.
  • Vaccination is a key strategy for controlling EV-A71 outbreaks.

Purpose of the Study:

  • To review recent progress in the development of EV-A71 vaccines.
  • To summarize the current landscape of EV-A71 vaccine candidates.

Main Methods:

  • Literature review of recent research on EV-A71 vaccine development.
  • Analysis of licensed and investigational EV-A71 vaccine platforms.

Main Results:

  • Three inactivated, whole EV-A71 vaccines are licensed by China's NMPA.
  • Alternative vaccine strategies, including virus-like particles and recombinant VP1 (capsid protein) vaccines, are under development.

Conclusions:

  • Continued research into diverse EV-A71 vaccine platforms is crucial.
  • Vaccine development aims to mitigate the impact of EV-A71-related diseases.